Adjuvant Therapies and Markers of Post-Surgical Minimal Residual Disease II: Adjuvant Therapies of the Various Primary Tumors

Front Matter....Pages I-XI
Wilms’ Tumor: Assessment and Treatment of Residual Disease....Pages 1-4
Adjuvant Therapy in the Management of Osteosarcoma: Need for Critical Reassessment....Pages 5-15
Adjuvant Therapy of Operable Primary Osteosarcoma-Cancer and Leukemia Group B Experience....Pages 16-24
Adriamycin in the Adjuvant Treatment of Operable Osteosarcoma....Pages 25-27
Randomized Trial of Adjuvant Chemotherapy in Osteogenic Osteosarcoma: Comparison of Altering Sequential Administrations of High Doses of Adriamycin, Methotrexate, and Cyclophosphamide with a 6-Month Administration of High-Dose Adriamycin Followed by a Low-Dose Semicontinuous Chemotherapy....Pages 28-32
Biochemistry of the Citrovorum Factor Rescue Effect in Normal Bone Marrow Cells After High-Dose Methotrexate Treatment: Implications for Therapy....Pages 33-39
Adjuvant Interferon Treatment of Human Osteosarcoma....Pages 40-44
Current Results With a Combined Treatment Approach to Localized Ewing’s Sarcoma....Pages 45-51
EORTC/GTO Adjuvant Chemotherapy Program for Primary Ewing’s Sarcoma: Results at 5 Years....Pages 52-59
Adjuvant Treatment of Soft Tissue Sarcoma in Children and Adults....Pages 60-74
Place and Role of Radiotherapy After Surgery for Breast Cancer....Pages 75-79
Combined Modality Management of Operable Breast Cancer....Pages 80-97
Treatment of Early Breast Cancer With Adriamycin-Cyclophosphamide With or Without Radiation Therapy: Initial Results of a Brief and Effective Adjuvant Program....Pages 98-104
Results of a Randomized Trial of Prophylactic Chemotherapy in T 3 -T 4 Breast Cancer Patients Previously Treated by Radiotherapy....Pages 105-108
Four Drug Combination Cytotoxic Chemotherapy Following Surgery for Breast Cancer....Pages 109-112
Pilot Study on Adjuvant Chemotherapy and Hormonal Therapy for Irradiated Inoperable Breast Cancer....Pages 113-117
Ovarian Irradiation and Prednisone Following Surgery and Radiotherapy for Carcinoma of the Breast....Pages 118-122
Adjuvant Therapy of Stage II, III Breast Cancer....Pages 123-128
Randomized Trial With Poly A-Poly U as Adjuvant Therapy Complementing Surgery in Patients With Breast Cancer: In Vitro Study of Cellular Immunity....Pages 129-138
Levamisole: As Adjuvant to Cyclic Chemotherapy in Breast Cancer....Pages 139-145
Laparoscopy and Peritoneal Cytology as Markers in the Follow-Up of Ovarian Epithelial Tumors....Pages 146-151
Radiotherapy in Ovarian Cancer for Post-Surgical Minimal Residual Disease....Pages 152-156
Chemotherapeutic Sensitivity of Minimal Residual Disease Following Surgical Excision of Ovarian Carcinoma....Pages 157-159
Chemoimmunotherapy for Advanced Ovarian Carcinoma With Adriamycin-Cyclophosphamide ± BCG: Early Report of a Southwest Oncology Group Study....Pages 160-165
Active Specific Immunotherapy in Ovarian Cancer....Pages 166-173
Clinical Studies on PSK: Combination Therapy of PSK With Radiation in Cancer of the Uterine Cervix....Pages 174-177
Irradiation as Adjuvant Therapy in the Management of Testicular Tumors....Pages 178-185
Adjuvant Chemotherapy in Embryonal Carcinoma of the Testis....Pages 186-191
Adjuvant Chemotherapy of Testicular Carcinoma: Need for Evaluation of Curative Strategies....Pages 192-200
Results of Cytostatic Therapy of Metastasizing Testicular Tumors....Pages 201-207
Treatment of Patients With Gastric Cancer by Surgery, Radiotherapy, and Chemotherapy: Preliminary Results of an EORTC Randomized Study....Pages 208-211
Chemotherapy for Known Residual Disease After Resection of Gastric and Colorectal Cancer....Pages 212-216
Adjuvant Treatment With Razoxane (ICRF 159) Following Resection of Cancer of the Stomach....Pages 217-221
Adjuvant Chemotherapy in Large-Bowel Cancer: Demonstration of Effectiveness of Single Agent Chemotherapy in a Prospectively Controlled, Randomized Trial....Pages 222-230
Ongoing Trials in the Surgical Adjuvant Management of Colorectal Cancer....Pages 231-235
Clinical Studies on PSK: Combination Therapy of PSK With Surgery and Chemotherapy....Pages 236-240
Role of Radiotherapy as an Adjuvant Therapy in Operable Bronchus Carcinoma....Pages 241-241
Influence of Postoperative Radiotherapy on Local Recurrence and Survival of Bronchial Epidermoid Carcinoma With Regard to Nodal Status: Preliminary Results of the EORTC Protocol 08741....Pages 242-243
Preliminary Trends of the EORTC Study Comparing Postoperative Chemotherapy, Immunotherapy, Chemoimmunotherapy or Abstention in Squamous Cell Bronchial Carcinoma....Pages 244-245
Adjuvant Chemotherapy of Post-Surgical Minimal Residual Bronchial Carcinomas....Pages 246-259
Attempt at Immunotherapy With Living BCG in Patients With Bronchus Carcinoma....Pages 260-267
Adjuvant Therapy With Levamisole in Resectable Lung Cancer....Pages 268-277
Specific Active Immunochemotherapy in Lung Cancer: A Survival Study....Pages 278-285
Patterns of Recurrence After Regional BCG Immunotherapy of Bronchial Cancer....Pages 286-291
Intrapleural BCG in Operable Lung Cancer....Pages 292-296
Adjuvant Chemoimmunotherapy of Head and Neck Cancer....Pages 297-308
Adjuvant Treatment of Tongue and Floor of the Mouth Cancers....Pages 309-317
First Results of a Randomized Trial on Immunotherapy of Head and Neck Tumors....Pages 318-323
Adjuvant Trial of Levamisole in Patients With Squamous Cancer of the Head and Neck: A Preliminary Report....Pages 324-333
Adjuvant Chemotherapy Following Radical Radiotherapy in T3 Bladder Carcinoma....Pages 334-337
Adjuvant Therapy of T1 Bladder Carcinoma: Preliminary Results of an EORTC Randomized Study....Pages 338-345
Adjuvant Chemotherapy or Chemoimmunotherapy in the Management of Primary Malignant Melanoma of Level III, IV, or V....Pages 346-358
Immunotherapy for Recurrent Malignant Melanoma: Efficacy of BCG in Prolonging the Postoperative Disease-Free Interval and Survival....Pages 359-362
Results of a Nonrandomized Trial in Malignant Melanoma Patients (Clark’s Stages III–V) Treated by Post-Surgical Chemoimmunotherapy....Pages 363-366
Value of Adjuvant Therapy With Bacille Calmette Guerin (BCG) or Dimethl Triazeno Imidazole Carboximide (DTIC) in the Control of Minimal Residual Disease in Stage II Melanoma....Pages 367-374
Controlled Study for Prolonged Chemotherapy, Immunotherapy, and Chemotherapy Plus Immunotherapy as an Adjuvant to Surgery in Malignant Melanoma (Trial 6): Preliminary Report....Pages 375-379
Adjuvant Therapy in Malignant Melanoma: A Trial of Immunotherapy, Chemotherapy, and Combined Treatment....Pages 380-386
Malignant Melanoma (Stage 1): A Clinical Trial of Adjuvant BCG Immunotherapy....Pages 387-392
Adjuvant Chemotherapy With Nitrosourea Compounds Following Surgery Plus Radiotherapy in Glioblastoma Multiforme....Pages 393-398
Treatment of Adult Malignant Gliomas....Pages 399-407
Adjuvant Chemotherapy in Malignant Brain Gliomas....Pages 408-411
Adjuvant Therapy for Residual Disease in Children With Medulloblastoma....Pages 412-422
Radiochemotherapy of Postoperative Minimal Residual Disease in Neuroblastoma....Pages 423-430
Adjuvant Systemic Therapy of Cancer: Rationale for Future Trials....Pages 431-438
Some New Chemotherapeutic Agents and Combinations Possibly Available for New Adjuvant Therapies of Minimal Disease....Pages 439-448
Third Generation of Systemic Adjuvants of Immunity: Experimental Basis for Adjuvant Combinations....Pages 449-457
Interrelationship Between Chemotherapy and Immunotherapy in the Treatment of Disseminated Disease....Pages 458-464
Concluding Remarks....Pages 465-465
Back Matter....Pages 467-468